  |
FDA MedWatch - March 2014 Drug Safety Labeling Changes includes 30 products with revisions to Prescribing Information
The MedWatch March 2014 Safety Labeling Changes posting includes 30 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.
The "Summary Page" provides a listing of product names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm392205.htm
The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:
Stavzor (Valproic acid)
Xarelto (rivaroxaban)
Diflucan (fluconazole)
Evamist (estradiol transdermal spray)
Sodium Iodide I-131 Therapeutic Solution
Azulfidine (sulfasalazine tablets, USP)
Erwinaze (asparaginase Erwinia chrysanthemi)
Herceptin (trastuzumab)
Jevtana (cabazitaxel)
Miacalcin (calcitonin-salmon)
Nexium (esomeprazole sodium)
Prilosec (omeprazole)
Selzentry (maraviroc)
Revatio (sildenafil)
Ultane (sevoflurane), Ultane NovaPlus (sevoflurane)
Viagra (sildenafil citrate)
Vimovo (naproxen/esomeprazole magnesium)
Xeljanz (tofacitinib)
Xifaxan (rifaximin)
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
